The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.

Start Date01 Dec 2026

Sponsor / Collaborator

Eli Lilly & Co.

NCT07881458

/ Not yet recruitingPhase 3

A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.

Start Date01 Nov 2026

Sponsor / Collaborator

Eli Lilly & Co.

CTIS2026-525919-14-00

/ Not yet recruitingPhase 3

J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

Start Date01 Oct 2026

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Eloralintide

100 Translational Medicine associated with Eloralintide

100 Patents (Medical) associated with Eloralintide

Literatures (Medical) associated with Eloralintide

01 Oct 2026·PHARMACOLOGICAL RESEARCH

Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

Review

Author: Borner, Tito ; Fischer, Sophia L

Amylin-based pharmacotherapy has re-emerged as a promising strategy for the treatment of obesity and metabolic disease with pharmacological and neural mechanisms distinct from incretin-based therapies. Amylin is a pancreatic β-cell hormone co-secreted with insulin that contributes to postprandial glucose regulation, slows gastric emptying, suppresses glucagon secretion, and promotes satiation through actions in the central nervous system. Recent advances in peptide engineering, lipidation, and reversible albumin binding have enabled the development of long-acting amylin-based agents, including cagrilintide, eloralintide, petrelintide and NN1213. These therapies differ in their pharmacokinetic properties and receptor selectivity, ranging from more selective amylin receptor agonists to dual amylin/calcitonin receptor agonists. This distinction may be critical for understanding both efficacy and tolerability, as calcitonin receptor engagement, exposure kinetics, and downstream neural circuit recruitment may influence whether reduced food intake reflects physiological satiation or aversive signaling. In this review, we summarize the biology of amylin signaling, the historical development of amylin-based therapeutics, and the emerging clinical landscape of long-acting amylin analogs. We place particular emphasis on the tolerability profile of this drug class and discuss how receptor pharmacology, hindbrain and parabrachial circuitry, species differences, and pharmacokinetic exposure may shape nausea, malaise, and emesis. Understanding how amylin-based therapies dissociate weight-loss efficacy from gastrointestinal intolerance may guide the rational design of next-generation anti-obesity drugs with improved clinical utility.

01 Sep 2026·DIABETES OBESITY & METABOLISM

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Review

Author: le Roux, Carel W. ; Alhazmi, Abdulhameed

ABSTRACT:

Aims:

The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.

Materials and Methods:

We conducted a narrative review of amylin‐based therapies that were approved or remained in human clinical development for obesity as of 30 April 2026. PubMed/MEDLINE, ClinicalTrials.gov, Google Scholar, company press releases, investor reports, and major congress abstracts were searched for relevant preclinical and clinical evidence.

Results:

Amylin, co‐secreted with insulin from pancreatic β‐cells, slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms. Pramlintide, the first approved amylin analogue, established proof of concept but was limited by modest efficacy and frequent dosing. More recently, long‐acting amylin‐based therapies, including cagrilintide, eloralintide, petrelintide, MET‐233i, ABBV‐295, and AZD6234, as well as combination approaches such as cagrilintide with semaglutide and zenagamtide, have demonstrated clinically meaningful weight loss with generally favorable tolerability profiles.

Conclusions:

Amylin‐based therapies represent a promising addition to the evolving treatment landscape of obesity. Their emerging efficacy as both standalone and combination therapies supports a multi pathway approach to addressing the biological complexity and heterogeneity of the disease.

01 May 2026·Endocrinology, diabetes & metabolism

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis

Review

Author: Khalil, Ibrahim ; Kamrul‐Hasan, A. B. M. ; Dutta, Deep ; Mahajan, Kunal ; Pappachan, Joseph M. ; Banerjee, Mainak

ABSTRACT:

Background:

Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta‐analysis (NMA) framework.

Methods:

We conducted a frequentist random‐effects NMA of randomized controlled trials comparing novel ABTs with placebo or active comparators in R. Primary outcome was the percent change in body weight from baseline. Secondary outcomes included absolute weight changes, anthropometric measures, and overall and specific GI adverse events (AEs). Treatments (including dose strata) were compared with placebo within a single network and ranked using P scores.

Results:

Six trials ( N = 4642; 12–68 weeks) were included. Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference −23.95%; P score 1.00), followed by HiD eloralintide (−18.01%; P score 0.89) and HiD CagriSema (−17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (−11.45%) and liraglutide 3.0 mg (−6.4%). Almost similar patterns were observed for absolute weight, body mass index, waist circumference and categorical weight‐loss thresholds. GI AEs, nausea, vomiting and constipation were more common with HiD ABTs, especially oral amycretin and CagriSema, while diarrhoea mainly increased with semaglutide 2.4 mg. Only HiD CagriSema increased AE‐related discontinuation.

Conclusions:

Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short‐ to medium‐term weight loss but may also increase GI AEs; given sparse, low‐certainty data, these findings are preliminary and require confirmation in larger trials.

Trial Registration:

The meta‐analysis was registered in PROSPERO (CRD420261340457). The review protocol summary can be accessed at the PROSPERO website ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420261340457 )

News (Medical) associated with Eloralintide

19 Oct 2026

·www.biospace.com

Should amylin have been obesity therapeutics’ primary target from the start?

iStock, mrgao While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism. As Novo’s amylin/GLP-1 combo CagriSema nears possible FDA approval and amylin-targeting assets from Eli Lilly and Zealand Pharma yield late-stage data, experts are touting the potential of the amylin approach to be a more tolerable option for weight management than the ubiquitously popular GLP-1s. “It’s a great mechanism that everyone should be paying attention to,” Hyung Heon Kim, president and CEO of MetaVia, said during a BioSpace webinar last month. BMO Capital Markets Head of Healthcare Research Evan Seigerman agreed, calling amylin “the next hot target” in the obesity space. The weight loss benefits of GLP-1s—initially indicated for diabetes—were a serendipitous discovery, Seigerman noted. But the analyst said he was struck by a comment from a key opinion leader who told him that if the biopharma industry had been focused on weight loss 10 years ago, amylin would have been the target of choice. Events Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment. September 9, 2026 · 1 min read · Jef Akst Read more Why amylin? Eli Lilly’s Zepbound and Novo’s Wegovy, and the other GLP-1 drugs in their portfolios or under development by biopharma writ large, work by activating the GLP-1 receptors to trigger the secretion of insulin and inhibition of glucagon release. In so doing, the medicines help to balance appetite and food cravings. But they don’t work for everyone, and amylin-targeting molecules could bust through weight loss plateaus in order to treat patients who may not respond well to GLP-1 drugs like Lilly’s Zepbound or Novo’s Wegovy, Seigerman said. “[Key opinion leaders] need something else like this in their armamentarium because not all patients respond to either one of them,” he added. GLP-1-based medicines also come with myriad side effects, most commonly gastrointestinal. There is a belief among experts that amylin-based weight loss drugs might offer a gentler option, with fewer adverse effects. Roche CEO Thomas Schinecker talked up the tolerability of his company’s Zealand Pharma–partnered amylin analog petrelintide. “If you don’t want side effects, you can take a highly tolerable amylin” drug, Schinecker told reporters in April during Roche’s first-quarter 2026 earnings call. Amylin/GLP-1 agonist combo therapies could achieve the same level of weight loss but with better tolerability by including lower doses of GLP-1 than do current monotherapies, Seigerman said. Indeed, Novo in June touted “low” dropout rates in the REDEFINE-1 and REDEFINE-2 trials of CagriSema, which combines semaglutide and the long-acting amylin analog cagrilintide. Patients in REDEFINE-1 lost 22.7% of their body weight at 68 weeks—below Novo’s own projections of around 25% but on par with current GLP-1 drugs. “Taking the best GLP-1 out there at this point in time, adding essentially an amylin . . . you’re able to get efficacy beyond where people may plateau on [semaglutide] for sure, and maybe even Zepbound,” Seigerman said of CagriSema. As to the demand for these therapies, Seigerman pointed to the bidding war between Novo and Pfizer last year over fledgling obesity biotech Metsera—a prize Pfizer ultimately won for nearly $10 billion. “When you talk to Pfizer and Novo about the Metsera bidding war . . . they were both going at this company because they wanted their amylin,” he said. Just months before the bidding war began, an ultra-long-acting amylin injection the biotech was developing elicited 8.4% placebo-adjusted weight loss at 36 days in a Phase 1 trial . The state of play Novo is nearing the regulatory finish line with CagriSema. The Danish pharma filed for FDA approval of its amylin combo last December, and analysts are anticipating a decision this quarter. If approved, CagriSema would be the first amylin drug to hit the market for weight loss, but it has many potential competitors in the pipeline. Novo’s chief rival Eli Lilly stole headlines at the European Association for the Study of Diabetes (EASD) annual meeting a few weeks ago, revealing robust weight loss generated by a combination of its amylin agonist eloralintide and powerhouse dual GIP/GLP-1 agonist Zepbound. In the Phase 2b trial, patients with obesity or overweight and type 2 diabetes who took the combo, called EloraTZP, lost an average of 23.3% of their weight at the 48-week mark, compared to 14.8% for those given Zepbound alone and 3% for placebo comparators. Obesity Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3 EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and type 2 diabetes, setting up the launch of a Phase 3 trial before the end of the year. September 30, 2026 · 3 min read · Heather McKenzie Read more The trial did record muddled safety data, with adverse event–tied discontinuations across the dosing groups of EloraTZP ranging from 10.8% and 27%, compared with 0% to 10.8% for eloralintide alone, 2.9% for tirzepatide only and 16.7% for placebo. EloraTZP’s Phase 2 results were “met with mixed reaction owing to the tolerability trade-off,” BNP Paribas wrote in an Oct. 5 note, which noted tolerability as a key theme at EASD. Nevertheless, the data package as a whole was enough for Lilly to take EloraTZP to Phase 3. Meanwhile, the pharma is expecting results from a Phase 3 study of eloralintide as a monotherapy in 2028. Analysts are expecting big things from the drug. “We expect eloralintide to be a mega-blockbuster given its differentiated benefit-tolerability pro potential role for patients who failed GLP-1 therapy due to efficacy or tolerability challenges,” Leerink Partners wrote in a note to investors on Sept. 15. As for Zealand’s Roche-partnered petrelintide, the companies reported Phase 2 data last week that William Blair found both “intriguing” and “underwhelming.” The long-acting human amylin analog elicited up to 9.2% mean weight loss at week 28 depending on the dose—which William Blair said was comparable to eloralintide and Zepbound and superior to Wegovy at the same time point. But the analysts were less impressed by petrelintide’s ability to lower blood sugar. This isn’t the first time petrelintide has failed to impress analysts and investors. In March, the investigational drug lowered body weight by more than 10% after 42 weeks in a mid-stage study . While the result fell well short of analyst expectations, minimal side effects were reported in the trial. “We believe Zealand achieved the goal of demonstrating highly encouraging tolerability for petrelintide, though the magnitude of weight loss disappointed,” William Blair wrote at the time. As clinical data begin to differentiate the field, Novo is looking ahead to a potential launch of CagriSema. The asset has had a rocky developmental journey, missing Novo’s own projections for the therapy in a December 2024 readout from the Phase 3 REDEFINE 1 trial and falling to Zepbound in the head-to-head Phase 3 REDEFINE 4 trial in February. Last month, however, CagriSema did best Lilly’s GIP/GLP-1 agonist in another Phase 3 test, REIMAGINE 5 . Seigerman described CagriSema as “a bit of a sleeper asset.” Whichever next-gen weight loss assets eventually steal market share, amylin will almost undoubtedly be among them. Seigerman cited his conversation about how it may have been the top choice over GLP-1s if the field could start over. “That says to me,” he said, “that amylin is going to be very important.” Weight loss Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off. February 23, 2026 · 4 min read · Annalee Armstrong Read more

Clinical ResultPhase 2Phase 3Drug Approval

13 Oct 2026

·www.genohopebio.com

Lilly's EloraTZP (combination Of Eloralintide And Tirzepatide) Delivered Greater Weight Loss And A1C Reduction Vs. Tirzepatide 15 Mg in Adults With Obesity And Type 2 Diabetes

Oct 13, 2026 View: 106 Leave a message Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study, Lilly will initiate Phase 3 trials of EloraTZP in Q4 2026 INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist, in 367 adults with obesity or overweight and type 2 diabetes. At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering substantial weight loss and A1C reduction. Results from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. EloraTZP was developed to simultaneously activate three complementary nutrient-stimulated hormones: GIP, GLP-1, and amylin, with minimal activity at the calcitonin receptor. These substances are released naturally by the body after eating, with each acting through its own distinct receptor to help regulate hunger and blood sugar.1 "Obesity and type 2 diabetes are interconnected, and we are seeing the potential benefit of targeting multiple hormonal pathways to address both," said Liana K. Billings, M.D., Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health, Evanston, Illinois, and lead author. "Across the dose combinations studied with eloralintide and tirzepatide, participants had substantial weight loss alongside meaningful reductions in A1C. These are outcomes that matter to patients. We need to continue building on these findings so that, in the future, we can offer patients more treatment options that address both weight and glucose and better reflect the complexity of living with type 2 diabetes and obesity." Eloralintide alone reduced body weight by up to an average of 28.6 lbs (12.3%) and A1C by up to an average of 1.4%, while tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%) and A1C by 2.4%. Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) and lowered their A1C by up to an average of 2.9% at 48 weeks, beyond what either medicine achieved alone. Phase 2 Efficacy Estimand Results2 Primary Endpoint: Change in body weight from an avg. baseline of 232.4 lbs (105.4 kg)i Secondary endpoint: Change in A1C from an avg. baseline of 8.1% Elora 3 mg + TZP 5 mg -13.2 % -30.7 lbs -2.2 % Elora 6 mg + TZP 5 mg -19.4 % -45.1 lbs -2.7 % Elora 6 mg + TZP 10 mg -19.9 % -46.2 lbs -2.6 % Elora 9 mg + TZP 15 mg -23.3 % -54.1 lbs -2.9 % TZP 15 mg -14.8 % -34.4 lbs -2.4 % Elora 3 mg -8.2 % -19.1 lbs -1.1 % Elora 6 mg -12.3 % -28.6 lbs -1.4 % Elora 9 mg -11.1 % -25.8 lbs -1.3 % Placebo -3.0 % -7.0 lbs -0.3 % iPrimary endpoint was percent change in body weight for EloraTZP vs. placebo. All other comparisons were secondary endpoints. The most common adverse events were gastrointestinal-related and generally mild or moderate, occurring primarily during dose escalation. These events were seen more frequently in the combination arms than with eloralintide or tirzepatide alone. Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo. "Lilly continues to pioneer new medicines for people living with obesity and diabetes, building on our scientific track record with tirzepatide, the first approved GIP and GLP-1 dual agonist, and retatrutide, our investigational triple agonist," said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health. "EloraTZP represents our next frontier, pairing a selective amylin receptor agonist with tirzepatide, which could be an additive and more physiological approach to managing metabolic health. We are highly encouraged by our Phase 2 results with EloraTZP and look forward to quickly initiating Phase 3 studies." Eloralintide is already being evaluated as a single agent in Phase 3 trials for the treatment of obesity. Lilly plans to initiate Phase 3 studies of an EloraTZP co-formulation product by the end of 2026 using an optimized escalation schedule. About EloraTZP EloraTZP is an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist and the active ingredient in Zepbound and Mounjaro. By engaging both amylin and incretin pathways concurrently, EloraTZP has the potential to improve weight and blood sugar through the body's naturally occurring metabolic signals. In the Phase 2b study (NCT06603571), eloralintide and tirzepatide were administered as separate injections in adults with obesity or overweight and type 2 diabetes. Lilly plans to advance an EloraTZP co-formulation product into Phase 3 by the end of 2026. About eloralintide Eloralintide is an investigational once-weekly, selective amylin receptor agonist previously known as LY3841136.3,4 Eloralintide has the potential to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness. Phase 3 trials of eloralintide for the treatment of obesity and in adults with obesity or overweight with or without type 2 diabetes are currently ongoing. Lilly has also conducted a Phase 2b study (NCT06230523) comparing the efficacy and safety of once-weekly eloralintide with placebo in adults with obesity or overweight and at least one weight-related comorbidity without type 2 diabetes.5 About Zepbound (tirzepatide) injection Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity. About the study The Phase 2b study (NCT06603571) was a 48-week, parallel-group, double-blind, placebo-controlled study to investigate weight management with eloralintide and Zepbound, alone or in combination, in adult participants with obesity or overweight with type 2 diabetes. The trial randomized 367 participants in the U.S. and Argentina in a 1:1:1:1:1:1:1:1:1:1 ratio to placebo, eloralintide, tirzepatide or EloraTZP. The primary objective of the study was to demonstrate that eloralintide in combination with Zepbound is superior to placebo in percent change in body weight from baseline at 48 weeks. All participants taking eloralintide started the study at 1 mg or 3 mg and escalated to their final target dose of 6 mg or 9 mg. All participants taking a combination of eloralintide and tirzepatide started the study at eloralintide 1 mg or 3 mg and tirzepatide 2.5 mg and escalated every four weeks until reaching their target dose. All participants taking tirzepatide started the study at 2.5 mg and escalated every four weeks until reaching their target dose of 15 mg. For some participants taking eloralintide as an add-on to tirzepatide, eloralintide was administered at week 24 starting with 3 mg and escalated to 6 mg after four weeks. Endnotes and References 1,Hayes MR, Mietlicki-Baase EG, Kanoski SE, De Jonghe BC. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu Rev Nutr. 2014;34:237-260. 2,The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) for 48 weeks. 3,Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74 (Supplement_1):849-P. https://doi.org/10.2337/db25-849-P 4,Bhattachar SN, Tham L-S, Tidemann-Miller B, et al. 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity-Phase 1 Proof of Concept. Diabetes 2025;74 (Supplement_1):882-P. https://doi.org/10.2337/db25-882-P 5,Eli Lilly & Company. (November 6, 2025). Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Eli Lilly and Company News Release. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

Phase 2Clinical ResultDrug ApprovalPhase 3

08 Oct 2026

·firstwordpharma.com

Zealand touts another weight-loss win for petrelintide, but HbA1c results fail to stand out

A week after sharing detailed data from a mid-stage obesity study of petrelintide, Roche and Zealand Pharma have posted Phase II findings for the amylin analogue in patients with type 2 diabetes. While petrelintide met its weight-loss primary endpoint, its effect on HbA1c levels failed to impress, as the company's shares ticked down about 5% on Wednesday. The latest readout comes from the Phase II ZUPREME-2 trial involving 220 people with overweight or obesity and type 2 diabetes who were randomised to receive one of three dose levels of petrelintide injection — escalated every fourth week — or placebo. Participants had a mean baseline BMI of 36.3 kg/m2 and a mean baseline HbA1c of 8%. After 28 weeks, patients taking petrelintide achieved up to 9.2% mean weight loss from baseline, based on the efficacy estimand, compared with 2% for placebo.The results are roughly in line with the Phase II ZUPREME-1 trial of the amylin analogue, which enrolled patients with obesity, without diabetes. Updated data, presented at the European Association for the Study of Diabetes (EASD) meeting last week, showed mean weight reductions from baseline reached up 9.8% at week 28. Petrelintide also achieved a tolerability profile similar to placebo. The most common adverse events (AEs) in ZUPREME-2 associated with the experimental treatment were gastrointestinal (GI), though "the vast majority" were mild, the drugmaker said. Patients taking the amylin analogue had a treatment discontinuation rate due to GI AEs of 1.9% versus 1.7% with placebo. Blood sugar impact?For a key diabetes-specific endpoint, Zealand said petrelintide demonstrated clinically relevant, placebo-adjusted HbA1c reductions ranging from 0.61% to 0.88% across all dosing groups. Eli Lilly and Novo are both developing co-formulations of their respective flagship GLP-1 drugs with an amylin-targeting component; the former's EloraTZP adds amylin receptor agonist eloralintide to GLP-1/GIP agonist tirzepatide, while Novo's CagriSema comprises semaglutide and cagrilintide, a long-acting amylin analogue. While recent readouts for EloraTZP and CagriSema aren't directly comparable to petrelintide, they're illustrative of the HbA1c reductions investors are hoping to see in diabetes studies. At EASD, Lilly reported data from a Phase IIb study of EloraTZP demonstrating a placebo-adjusted 2.6% reduction in HbA1c for the highest tested dose at week 48 (see – KOL Views Q&A: Amylin could fill gaps where GLP-1s fall short).Earlier in September, Novo shared 60-week findings from the Phase III REIMAGINE 5 trial showing a 1.71-percentage-point reduction in HbA1c for CagriSema (see – Physician Views Results: Novo's CagriSema wins clinician enthusiasm in diabetes — but access and Lilly's tirzepatide loom large).Zealand said full results from ZUPREME-2 will be shared at an upcoming meeting; a Phase III programme evaluating petrelintide monotherapy for chronic weight management is already under way.

Phase 2Clinical ResultPhase 3

100 Deals associated with Eloralintide

External Link

KEGG	Wiki	ATC	Drug Bank
D12886	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 3	United States	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	China	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Japan	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Australia	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Brazil	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Canada	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Germany	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	India	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	South Korea	Eli Lilly & Co.	10 Feb 2026
Sleep Apnea, Obstructive	Phase 3	Spain	Eli Lilly & Co.	10 Feb 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2026	Phase 1	Overweight \| Obesity	160	Elora+TZP	ldngkujcxy(joalfizsua) = The elora plus TZP arms had higher rates of all treatment-emergent adverse events (TEAEs) than PBO plus TZP or elora plus PBO. The most common TEAEs were gastrointestinal events; most were mild to moderate in severity. lzfsuchali (cinwtlifap )	Positive	28 Sep 2026
NCT06230523 (CTgov)	Phase 2	Obesity	263	Placebo (Placebo)	pchinvipyu(ibociodkkw) = tqzhdijuyw jxnkgujszf (zbrgkibios, 0.91) View more	-	24 Jun 2026
				Eloralintide (1 mg Eloralintide)	pchinvipyu(ibociodkkw) = rmcgfpmklf jxnkgujszf (zbrgkibios, 1.60) View more
NCT06230523 (Pubmed \| Lancet)	Phase 2	Obesity	263	Eloralintide 1 mg	jfkwfqdkvj(yyncpjtjvf) = mcejosruwe xctffwvkou (sztbsgqvxn, -12.6 to -6.3)	Positive	01 Dec 2025
				Eloralintide 3 mg	jfkwfqdkvj(yyncpjtjvf) = oqeaaqqmeq xctffwvkou (sztbsgqvxn, -14.9 to -9.8)
NCT05295940 (Pubmed \| Mol Metab)	Phase 1	Obesity	48	Eloralintide	mbdkvgmqeq(tmhlipmnvx) = kemnifhzzs eztohmibal (qvxmsvaejm ) View more	Positive	01 Dec 2025
				Placebo	ziplrodzzt(desaqokeqh) = uvnvpjjpdu dqbpqdbfmw (sdddfghxht ) View more
NCT06230523 (Company_Website \| Lancet) Manual	Phase 2	Overweight \| Obesity	263	Eloralintide 1 mg	xbsnukmsto(bljbxevwoy) = acmscggqax tyqleqzoul (bgqpmjogbh ) Met	Positive	06 Nov 2025
				Eloralintide 3 mg	xbsnukmsto(bljbxevwoy) = vqqmvcalpn tyqleqzoul (bgqpmjogbh ) Met
NCT06916091 (ADA2025 \| NEWS) Manual	Phase 1	Obesity	100	Eloralintide dose1	oqvcdpebqh(flwergyvhs) = fxnpurgfqq tsekxchuny (zfauxvofjb ) View more	Positive	17 Jun 2025
				Eloralintide dose2	vwaikposeo(kwusbafwkk) = oqzxkgsuyb lysqczzvjh (coflhqxumt )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis